鶹ý

Wearables as Cancer Monitors; No China Price Break; Cancer Mystery in Appalachia

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

have the potential to become major contributors to precision cancer care. (UVA Health)

Biological therapy -- such as monoclonal antibodies and antibody-drug conjugates -- for solid tumors, accounting for about two thirds of all drugs. (GlobalData)

Preclinical studies suggest that diabetes may . (Memorial Sloan Kettering Cancer Center, Blood Advances)

Hopes for took a hit, as Coherus BioSciences "will not engage in heavily discounted pricing" for toripalimab (Loqtorzi), the first China-developed anti-PD-1 drug, expected to launch in the U.S. early next year. (FiercePharma)

The American Society of Clinical Oncology has launched a for patient-centered cancer care standards.

For reasons not yet clear, are twice the national average in Appalachian Kentucky. (JAMA Network Open)

More progress toward a that can detect the earliest signs of developing cancer. (The Rockefeller University, Cancer Discovery)

Responding to doctors' concern about access to their , the medical website Doximity has introduced DocDefender, a free service that removes doctors' addresses and phone numbers from public websites. (CNBC)

Artificial intelligence using scans was for determining the aggressiveness of certain sarcomas. (The Guardian, Lancet Oncology)

The in a final Medicare ruling that would cut an additional 2% from reimbursement for radiation oncology; ASTRO called for a legislative solution for declining Medicare physician payments.

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 鶹ý in 2007.